Menin inhibitors in AML: Where are we now, and where are we going?
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The di...
22 Maj 30min
Managing side effects of menin inhibitors in clinical practice
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach ...
21 Maj 7min
Mechanisms and rationale for menin inhibitor combination strategies in AML
The AML Hub was pleased to speak with Eunice Wang from Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies...
20 Maj 4min
Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care w...
19 Maj 32min
What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML?
The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials...
15 Maj 5min
Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with...
12 Feb 7min
Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a present...
11 Feb 14min
Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations
The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation fro...
19 Jan 20min
